Durvalumab Plus Tremelimumab in Pediatric Patients With Advanced Cancers

Researchers are conducting a phase 1/2 trial to evaluate durvalumab plus tremelimumab in pediatric patients with advanced cancers.

Related Keywords

Ashok Gupta ,Astrazeneca ,